BioSpace News Archive

Pelthos Therapeutics today announced it has appointed five seasoned industry professionals to serve on its Board of Directors.

Johnson & Johnson announced results for first-quarter 2024. “Johnson & Johnson’s solid first quarter performance reflects our sharpened focus and the progress in our portfolio and pipeline,” said Joaquin Duato, Chairman and Chief Executive Officer.

In October of 2023, the US FDA approved Novartis’ intravenous formulation of Cosentyx for the treatment of psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.

n-Lorem, a nonprofit Foundation , has collaborated with Across Healthcare, a technology innovator, to develop a first-of-its-kind submission platform and system that allows research physicians from across the United States to submit applications for treatment for their patients with nano-rare illnesses.

According to Nova One Advisor, the global diagnostic testing market is valued at USD 211.27 billion in 2023

Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that its common stock has been approved for quotation on the OTCQB market.

Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has approved SELARSDI injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced final results from the HD cohort of the Phase 4 START study, demonstrating positive real-world effectiveness, safety, adherence and satisfaction with the 4-week Titration Kit for AUSTEDO.